Pipeline

Stress Urinary Incontinence

Focused on unintentional and involuntary loss of urine caused by pelvic floor muscle weakness

The ability of a SARM to increase muscle mass may prove beneficial in postmenopausal women with stress urinary incontinence (SUI) where pelvic floor muscle weakness leads to unintentional loss of urine with physical activity.

The Company’s main focus is the potential treatment of stress urinary incontinence. In a Phase 2 proof-of-concept clinical trial, data from which were announced in September 2017, a daily dose of enobosarm 3 mg (GTx-024) substantially improved SUI in women, as well as related quality of life measurements. Top-line results from the Phase 2 proof-of-concept trial may be found here.

The Company currently has an ongoing, placebo-controlled Phase 2 clinical trial in postmenopausal women with SUI. The study, called ASTRID (Assessing Enobosarm for Stress Urinary Incontinence Disorder), is currently recruiting patients at various clinical trial centers across the United States. To see if you are eligible to participate in the clinical trial, click here.

More information on Stress Urinary Incontinence may be found here.